english.prescrire.org > Spotlight > 100 most recent > Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic

 COVID-19  Prescrire's editors are publishing an ongoing series of news updates featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view.


  • "Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease" (24 July 2020) > HERE
     
  • "Covid-19: remdesivir (Veklury°) authorised in the European Union, yet much remains unknown or uncertain" (13 July 2020) > HERE
     
  • "Covid-19 and severe breathing problems: dexamethasone reduced mortality in one trial" (24 June 2020) > HERE
     
  • "Lack of access to drug evaluation data: a recurrent problem, not confined to covid-19" (8 June 2020) > HERE
     
  • "Covid-19 and  hydroxychloroquine  (Plaquenil°): new data  show no evidence of efficacy"  (16 April 2020) > HERE
     
  • "New data on the  cardiac adverse effects  of the combination of  hydroxychloroquine  (Plaquenil°) with azithromycin (Zithromax° or other brands)" (16 April 2020) > HERE

  • "Covid-19 and hydroxychloroquine (Plaquenil°): still no conclusive results" (15 April 2020) > HERE

  • "Covid-19 and hydroxychloroquine: uncertainties and unanswered questions" (2 April 2020) > HERE

  • "Covid-19 and hydroxychloroquine: caution" (30 March 2020) > HERE
     
  • "Covid-19 and drug trials: what to make of the initial results?" (23 March 2020) > HERE

  • For more information in French, see www.prescrire.org > Dans l'actualité

©Prescrire 24 July 2020

For more updates, follow us on Facebook and Twitter

Facebook Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. > Follow us on Facebook or > Follow us on Twitter

Filet

Enjoy full access to Prescrire International, and support independent information

Share
Share on  Facebook Share on  Twitter
 
 
Read more:

All the subjects in
Prescrire's Spotlight
Free >